PRISM BioLab Co.,LTD
| Code | Sector | Market |
|---|---|---|
| 206A | Pharmaceuticals | Growth |
| Date of listing approval | 2024/05/27 |
|---|---|
| Expected Date | 2024/07/02 |
| Lead Underwriter | SMBC Nikko Securities Inc. |
| Description |
| Listed Shares(total) | 4,600,000 |
|---|---|
| Trading Unit | 100 |
| New Shares | 4,000,000 |
| Existing Shares | 600,000¡Êonly O.A.¡Ë |
| Shares Outstanding | PreIPO 31,354,800.00 |
| PostIPO 35,354,800.00 | |
| Paid Up Capital | PreIPO Y762,246,000 |
| PostIPO Y1,279,311,300 | |
| Expected Pricing Date | 2024/06/14 |
| Book Building Start | 2024/06/17 |
| Book Building End | 2024/06/21 |
| Fix Date | 2024/06/24 |
| Offering Starts | 2024/06/25 |
| Offering Ends | 2024/06/28 |
| Expect Pricing | Y435-Y450 |
| Notional PER (based on previous period) |
-22.79--23.57 |
| Notional PER(based on results forecast) | -10.88--11.26 |
| Offering Price | Y450 |
| Offering Price PER (based on previous period) |
-10.88--11.26 |
| Offering Price PBR (based on previous period) |
-13.04 |
| Offering Price PER (based on results forecast) |
-11.26 |
| Use of Funds Raised |
Financial Data
Units:Y1,000
| Fiscal Year End:2021/09 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | 58,801 |
| Current Profit | - | -153,707 |
| Net Profit | - | -155,989 |
| Net Assets | - | 1,092,912 |
| Fiscal Year End:2022/09 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | 554,396 |
| Current Profit | - | 78,666 |
| Net Profit | - | 72,962 |
| Net Assets | - | 1,674,930 |
| Fiscal Year End:2023/09 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | 112,926 |
| Current Profit | - | -497,550 |
| Net Profit | - | -526,914 |
| Net Assets | - | 1,148,015 |
| Recent Quarter 2024/03 |
||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | 115,482 |
| Current Profit | - | -322,855 |
| Net Profit | - | -336,052 |
| Net Assets | - | 2,311,962 |
| Results Forecast 2024/09 |
||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | 300,000 |
| Current Profit | - | -914,000 |
| Net Profit | - | -1,160,000 |
| Net Assets | - | - |
Per Share Units:Y1
| Fiscal Year End:2021/09 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | 0.00 | |
| Net Earning | - | - |
| Equity | -7.78 | -31.16 |
| Fiscal Year End:2022/09 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | 0.00 | |
| Net Earning | - | - |
| Equity | 2.67 | -15.41 |
| Fiscal Year End:2023/09 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | 0.00 | |
| Net Earning | - | - |
| Equity | -19.09 | -34.50 |
| Fiscal Year End:Interim Results 2024/03 |
||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | ||
| Net Earning | - | -11.57 |
| Equity | - | - |
| Fiscal Year End:Results Forecast 2024/09 |
||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | 0.00 | |
| Net Earning | - | -39.98 |
| Equity | - | - |
Comment
| ¢£Over allotment(600,000¡Ë |
Consolidated Subsidiaries
| Name | Address |
|---|
Underwriters
| Allocation | Underwriter | Tel |
|---|---|---|
| 0% | Nomura | 03-3211-1811 |
| 82% | SMBC Nikko Securities Inc. | 03-5644-3111 |
| 6% | Daiwa Securities Co. Ltd | 03-5555-2111 |
| 5% | Mizuho Securities Co., Ltd | 03-5208-3210 |
| 4% | SBI SECURITIES Co.,Ltd. | 03-5562-7210 |
| 1% | IwaiCosmo Securities Co.,Ltd. | 06-6229-2890 |
| 1% | Matsui Securities Co., Ltd | 03-5216-0606 |
| 1% | Marusan Securities Co., Ltd | 03-3272-5211 |
Data
| Date of incorporation | 2012/04/02 |
|---|---|
| Company address | Kanagawa 251-8555 |
| Telephone | 0466-53-8383 |
| President | |
| Homepage | https://prismbiolab.com/ |
| Auditor | KPMG AZSA LLC |
| Major Shareholders | |
|---|---|
| Shareholder Name | Ratio |
| 86.62% | |
| 16.30% | |
| 12.05% | |
| 11.09% | |
| 8.29% | |
| 6.99% | |
| 6.37% | |
| 5.23% | |
| 3.49% | |
| 3.49% | |
| 2.80% | |
| Number of Employees | 22 as of 2024/04/30 |
|---|---|
| Birth Date of Representative | 1963/05/18 |